Startseite>>Signaling Pathways>> Immunology/Inflammation>> FKBP>>Shield-1

Shield-1 (Synonyms: Shld1)

Katalog-Nr.GC38060

Shield-1 (Shld1) ist ein spezifischer, zellpermeabler und hochaffiner Ligand des FK506-bindenden Proteins-12 (FKBP) und kehrt die Instabilität um, indem es an mutiertes FKBP (mtFKBP) bindet und so eine bedingte Expression von mtFKBP-fusionierten Proteinen ermöglicht.

Products are for research use only. Not for human use. We do not sell to patients.

Shield-1 Chemische Struktur

Cas No.: 914805-33-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
667,00 $
Auf Lager
1mg
180,00 $
Auf Lager
5mg
405,00 $
Auf Lager
10mg
657,00 $
Auf Lager
25mg Please Inquire Please Inquire
50mg Please Inquire Please Inquire
100mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Shield-1 is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize the entire fusion protein[1][2].

[1]. Schoeber JP, et al. Conditional fast expression and function of multimeric TRPV5 channels using Shield-1. Am J Physiol Renal Physiol. 2009 Jan;296(1):F204-11. [2]. Li S, et al. Effects of Shield1 on the viral replication of varicella zoster virus containing FKBP tagged ORF4and 48. Mol Med Rep. 2018 Jan;17(1):763-770.

Bewertungen

Review for Shield-1

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Shield-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.